Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: A single-institution analysis

International Journal of Biological Markers

Volumn 25, Issue 2, 2010, Pages 104-111

  Guarneri, Valentina ^a   Barbieri, Elena ^a   Piacentini, Federico ^a   Giovannelli, Simona ^a   Ficarra, Guido ^a   Frassoldati, Antonio ^a   Maiorana, Antonino ^a   D'Amico, Roberto ^a   Conte, PierFranco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Breast cancer; Ki 67; Neoadjuvant chemotherapy; p53; Predictive factors; Primary systemic therapy; Prognostic factors; Tumor biomarkers

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MOLECULAR TYPING; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHENOTYPE; PREDICTION AND FORECASTING; PREOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR DIFFERENTIATION; UNIVARIATE ANALYSIS; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; EVALUATION STUDY; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PREDICTIVE VALUE; PREOPERATIVE PERIOD; REMISSION; SEGMENTAL MASTECTOMY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954939884     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500208     Document Type: Article

References (39)

1. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-93.
2. Gralow J R, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26: 814-9.
3. Kuerer H M, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-9.
4. Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20: 1304-10. (Pubitemid 34177437)
5. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-44.
6. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23: 9304-11.
7. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-8.
8. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95: 681-95. (Pubitemid 34845919)
9. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-12. (Pubitemid 36308152)
10. Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? Breast J 2009; 15: 146-54.
11. von Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008;10: R30.
12. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-6.
13. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006; 13: 293-325
14. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751-8
15. Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000; 60: 2155-62.
16. Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998; 79: 27-33.
17. Anelli A, Brentani RR, Gadelha AP, Amorim de Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer Ann Oncol 2003; 14: 428-32.
18. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36.
19. Bonnefoi H, Diebold-Berger S, Therasse P, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003; 14: 406-13.
20. Bidard FC, Matthieu MC, Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 2008; 19: 1261-5. (Pubitemid 351916575)
21. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50-6. (Pubitemid 30064975)
22. Geisler S, Børresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003; 9: 5582-8. (Pubitemid 37499478)
23. Makris A, Powles, TJ, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997; 3: 593-600. (Pubitemid 27211838)
24. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-65.
25. Fisher CJ, Gillett CE, Vojtèsek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994; 69: 26-31. (Pubitemid 24021818)
26. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
27. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
28. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349: 84-9.
29. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67. (Pubitemid 23289454)
30. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10. (Pubitemid 24359290)
31. Elledge RM, Allred GD. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treatment 1998; 52: 79-98. (Pubitemid 29056087)
32. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60.
33. Fan S, Cherney B, Reinhold W, Rucker K, O'Connor PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 1998; 4: 1047-54. (Pubitemid 28183408)
34. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 1997; 94: 9679-83.
35. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-9. (Pubitemid 26029571)
36. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-6.
37. Bull SB, Ozcelik H, Pinnaduwage D, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004; 22: 86-96. (Pubitemid 41095118)
38. Barbareschi M. Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Appl Immunohistochem 1996; 4:106-16.
39. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80: 1968-73.